Title: Outsourcing in China: How far can it go? By Vicky Qing Xia, BioPlan Associates

China’s biopharmaceutical services market is on pace to top $1 billion by 2021 In China, there are near daily trade news reports about the explosive growth in the pharmaceutical outsourcing industry, both for contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The booming biopharma industry in China has created business opportunities for CRO/CDMO companies, which is why these suppliers have become hot targets for investors. In our recent addition of “Advances in Biopharmaceutical Technology in China, 2nd ed.,” we note this increased influx of growth for CDMOs in China, and their continued future development.1 Much of this interest in outsourcing to China has also been identified in our “16th Annual Report and Survey of Biopharmaceutical Manufacturing.”2a We asked global respondents to consider their five-year time horizon (up to 2024) and evaluate their facility’s plans for future international (not domestic) outsourcing. We identified two dozen countries as potential outsourcing destinations. Among all respondents, the U.S. ranked highest again as a potential outsourcing destination, with 41.1% indicating there was a likelihood or strong likelihood that they would outsource production to facilities there—up from 30.1% in 2018. Surprisingly, this year, China moved up to the number 2 spot, with 29%—up from 21.4% in 2018 and just 16.2% in 2017 (see Figure 1).

Click Here For Complete Article Text


   Person Information
   Application Sequencing
 325412 - Pharmaceutical Preparation Manufacturing                
 541711 - Research and Development in Biotechnology                
Company  Product  Process  Other  Subjects  Event  Event  Date  Location  Publication  Publication  Date Text  Descriptor

  • Outsourcing




  • China


  • Contract Pharma


  • 8/1/2019


  • Article